- Home
- ERAS vs ARVN Comparison
ERAS vs ARVN Comparison
Compare ERAS & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- ARVN
- Stock Information
- Founded
- ERAS 2018
- ARVN 2015
- Country
- ERAS United States
- ARVN United States
- Employees
- ERAS N/A
- ARVN N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- ERAS Health Care
- ARVN Health Care
- Exchange
- ERAS Nasdaq
- ARVN Nasdaq
- Market Cap
- ERAS 396.6M
- ARVN 614.8M
- IPO Year
- ERAS 2021
- ARVN 2018
- Fundamental
- Price
- ERAS $1.43
- ARVN $6.70
- Analyst Decision
- ERAS Strong Buy
- ARVN Buy
- Analyst Count
- ERAS 6
- ARVN 19
- Target Price
- ERAS $4.83
- ARVN $21.19
- AVG Volume (30 Days)
- ERAS 1.5M
- ARVN 3.3M
- Earning Date
- ERAS 05-20-2025
- ARVN 05-01-2025
- Dividend Yield
- ERAS N/A
- ARVN N/A
- EPS Growth
- ERAS N/A
- ARVN N/A
- EPS
- ERAS N/A
- ARVN N/A
- Revenue
- ERAS N/A
- ARVN $426,900,000.00
- Revenue This Year
- ERAS N/A
- ARVN N/A
- Revenue Next Year
- ERAS N/A
- ARVN N/A
- P/E Ratio
- ERAS N/A
- ARVN N/A
- Revenue Growth
- ERAS N/A
- ARVN 498.74
- 52 Week Low
- ERAS $1.01
- ARVN $5.94
- 52 Week High
- ERAS $3.45
- ARVN $37.38
- Technical
- Relative Strength Index (RSI)
- ERAS 52.92
- ARVN 36.63
- Support Level
- ERAS $1.37
- ARVN $6.51
- Resistance Level
- ERAS $1.61
- ARVN $8.00
- Average True Range (ATR)
- ERAS 0.14
- ARVN 0.55
- MACD
- ERAS 0.00
- ARVN -0.08
- Stochastic Oscillator
- ERAS 53.09
- ARVN 17.68
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.